A NEW COST-EFFECTIVENESS FRAMEWORK FOR MODELING ANKYLOSING SPONDYLITIS TREATMENTS [MEETING ABSTRACT PMS52]
Even though the common Markov structure used in existing HTA submissions for AS treatments incorporates most aspects of disease progression, areas for improvement were identified. The proposed model matches clinical practice and improves decision making for biologic treatments.
Citation
Graham, C., Gunda, P., Miles, L., Jugl, S. M., Palaka, E., & McBride, D. (2016). A NEW COST-EFFECTIVENESS FRAMEWORK FOR MODELING ANKYLOSING SPONDYLITIS TREATMENTS [MEETING ABSTRACT PMS52]. Value in Health, 19(3), A234-A234. DOI: 10.1016/j.jval.2016.03.1152
